|
16th GAVI BOARD MEETING
Paris, France, 19-20 July, 2005
Summary Report
|
|
>>Back to the 16th GAVI Board Meeting
|
|
Documents
Presentation: Merceline Dahl-Regis, Investment case review team (
PPT - 193K)
Bridge Financing Investment Case (
PDF - 300K) |
|
4. Bridge financing investment case
- The feasibility of co-financing will depend upon the
willingness and ability of country governments and other donors to
contribute to vaccine costs.
- The process for handling countries in crises,
or those unable to meet their co-financing obligations, requires
further development.
- Explicit mechanisms for monitoring the
implementation of bridge financing will need to be established, so that
operations can be modified as needed.
- Policies must be developed and applied with
manufacturers and markets in mind. For example, some concern was
expressed regarding the setting of a so-called “working price” given
the risks of creating market constraints and the many variables in
calculating such a price. Even so, there was recognition of the need to
set a certain parameter for future planning and financial projections.
- Even though financing more expensive vaccines
is proving a significant challenge, the programmatic benefits of
combination vaccines are still highly valued by the countries.
DECISIONS
The Board:
4.1 Endorsed the three main principals of the bridge financing:
4.1.1 Flatline support (extending 100% support through 2007 – affects 11 countries)
4.1.2 The concept of a “working” price given the need
for a figure for planning and budgeting, with a request to come up with
a new name that better reflects its imprecision.
4.1.3 Co-financing, so that countries make commitments
to gradually increase non-GAVI contributions to the vaccine’s costs
over the years through 2015.
4.2 Agreed that the project management structure as
proposed needs to be reconsidered to ensure that it strengthens
capacity of countries and builds upon existing structures and capacity
of partners.
4.3 Endorsed the proposed budget envelope of $520
million as a provisional total, with the understanding that should
assumptions about vaccine price declines not materialize, the costs of
bridge financing would increase. The Board will need to be kept
regularly informed.
|
|
>>Back to the 16th GAVI Board Meeting
|
| |
|
|
Go
here for presentations
Go
here for documents
Topics:
-
Report from the field: Malawi
-
GAVI/Vaccine Fund in Phase 2—Executive Secretary Report
-
Investment case development, review and decision-making process
-
Bridge financing investment case
-
New vaccines in phase 2
-
IFFIm-Dependent Investment Cases
-
Long-term supply and procurement strategy
-
The International Finance Facility for Immunization
-
Immunization services support and health system strengthening
-
Technical support in phase 2
-
GAVI/VF 2006-07 Work Plan Framework
-
Yellow fever stockpile evaluation
|
|